Egrifta and Waist circumference increased - a phase IV clinical study of FDA data

Summary:

Waist circumference increased is reported as a side effect among people who take Egrifta (tesamorelin acetate), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Lisinopril, and have Lipodystrophy acquired.

The phase IV clinical study analyzes which people have Waist circumference increased when taking Egrifta. It is created by eHealthMe based on reports of 3,441 people who have side effects when taking Egrifta from the FDA, and is updated regularly.

What is Egrifta?

Egrifta has active ingredients of tesamorelin acetate. eHealthMe is studying from 3,443 Egrifta users. Check the latest studies of Egrifta.

What is Waist circumference increased?

Waist circumference increased is found to be associated with 170 drugs and 585 conditions by eHealthMe. Check the latest studies of Waist circumference increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

3,441 people reported to have side effects when taking Egrifta.
Among them, 16 people (0.46%) have Waist circumference increased.

Could Egrifta cause Waist circumference increased?

Among these 16 people:

How long have people been on Egrifta when they have Waist circumference increased? *

What is the gender of people who have Waist circumference increased when taking Egrifta? *

female: 0.0 %
male: 100 %

What is the age of people who have Waist circumference increased when taking Egrifta? *

What are other drugs people take besides Egrifta? *

Sertraline: 3 people, 18.75%
Lisinopril: 3 people, 18.75%
Testosterone Cypionate: 2 people, 12.50%
Tamsulosin: 2 people, 12.50%
Nuedexta: 2 people, 12.50%
Intelence: 2 people, 12.50%
Glipizide: 2 people, 12.50%
Gabapentin: 2 people, 12.50%
Desvenlafaxine: 2 people, 12.50%
Descovy: 2 people, 12.50%

What are other side effects people have besides Waist circumference increased? *

Drug Ineffective: 8 people, 50.00%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 31.25%
Weight Increased: 4 people, 25.00%
Injection Site Pain: 3 people, 18.75%
Gait Disturbance: 3 people, 18.75%
Glomerular Filtration Rate Decreased: 3 people, 18.75%
High Blood Cholesterol: 3 people, 18.75%
Mean Cell Volume Increased (more than normal average red blood cell volume): 3 people, 18.75%
Mean Cell Haemoglobin Increased (more than normal haemoglobin per red blood cell in a sample of blood): 3 people, 18.75%
Injection Site Mass: 3 people, 18.75%

What are the existing conditions these people have? *

Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 13 people, 81.25%
Type 2 Diabetes: 1 person, 6.25%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Egrifta and have Waist circumference increased?

- Check whether Waist circumference increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Egrifta:

Egrifta (3,443 reports)

Browse all side effects of Egrifta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Waist circumference increased:

Waist circumference increased (170 drugs)

Browse all the conditions that are associated with Waist circumference increased:

Waist circumference increased (585 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tesamorelin acetate (the active ingredients of Egrifta) and Egrifta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.